Quebec breathes new hope into lives of those affected by pulmonary arterial hypertension

Patients elsewhere in Canada hope for swift access to new treatment option now funded in Quebec VANCOUVER, Oct. 8, 2014 /CNW/ – The Pulmonary Hypertension Association of Canada (PHA Canada) was pleased to learn that a new treatment option for pulmonary arterial hypertension (PAH) is now being publicly funded in the province of Quebec. On […]

The post Quebec breathes new hope into lives of those affected by pulmonary arterial hypertension appeared first on Posts High Blood Pressure.

Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open

Silver Spring, Md. (PRWEB) September 29, 2014 The Pulmonary Hypertension Association has accredited its first six Pulmonary Hypertension Care Centers (PHCC) in a program that seeks to improve overall quality of care and ultimately improve outcomes of patients with pulmonary hypertension (PH), specifically pulmonary arterial hypertension (PAH) – a rare and debilitating disease of the […]

The post Pulmonary Hypertension Association Accredits First Six PH Care CentersApplication Process Now Open appeared first on Posts High Blood Pressure.

Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial …

Actelion Pharmaceuticals Ltd / Selexipag fulfills main endpoint in crucial Phase III GRIPHON outcome research in clients with lung arterial hypertension. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely in charge of the content of this announcement. ALLSCHWIL, SWITZERLAND – 16 June 2014 – Actelion Ltd (6: ATLN) today announced the top-line outcomes of the essential Phase III GRIPHON study in 1,156 clients with lung arterial hypertension (PAH) with selexipag, the first selective dental prostacyclin IP …

Press Release: Actelion: Selexipag meets primary

Actelion zu myNews hinzufügen Was ist das?-1 of 3- 15 Jun 2014 23:00:00 UTC  *DJ Actelion: Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension‘); } else { document.write(‘ ‘);fragAddGoogleAdsense(‘3′,’9679456044′,’535′,’125′,”,’2′,’2831469847’);document.write(“” + “ipt>”);document.write(”); } //–>    (MORE TO FOLLOW) Dow Jones Newswires    June 15, 2014 19:00 ET (23:00 GMT)- – 07 00 PM EDT 06-15-14 -2 of 3- 15 Jun 2014 23:00:00 UTC  Press Release: Actelion: Selexipag meets primary endpoint in pivotal …

Press Release: Actelion: Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with …

Actelion zu myNews hinzufügen Was ist das?-1 of 3- 15 Jun 2014 23:00:00 UTC  *DJ Actelion: Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension‘); } else { document.write(‘ ‘);fragAddGoogleAdsense(‘3′,’9679456044′,’535′,’125′,”,’2′,’2831469847’);document.write(“” + “ipt>”);document.write(”); } //–>    (MORE TO FOLLOW) Dow Jones Newswires    June 15, 2014 19:00 ET (23:00 GMT)- – 07 00 PM EDT 06-15-14 -2 of 3- 15 Jun 2014 23:00:00 UTC  Press Release: Actelion: Selexipag meets primary endpoint in pivotal …

Bayer Looking to Expand Adempas Label

The HealthCare section at Bayer (BAYRY) announced the initiation of a brand-new research on its lung high blood pressure (PH) medicine, Adempas (riociguat). The business launched a phase IIb RISE-IIP (Riociguat in Clients with Symptomatic Pulmonary High blood pressure connected with Idiopathic Interstitial Pneumonias) research study (n=120) on Adempas, which will certainly be evaluating the efficacy and safety and security of the medication in clients struggling with symptomatic PH linked with idiopathic interstitial pneumonia (: IIP). The research will be …

The Pulmonary Arterial Hypertension Foundation

PLESSISVILLE, QC, June 3, 2014 / CNW Telbec / – The Pulmonary Arterial High blood pressure Foundation – Quebec (HTAPQ) was incredibly disappointed with the recommendation made the other day by the Institut national d’excellence en santé et services sociaux (INESSS), which decided not to include Opsumit (macitentan) on the listing of medicines covered by Quebec’s public drug insurance plan. The President of the HTAPQ Foundation, Denis Cormier, states he was saddened to find out that people will be denied …

pulminary hypertension disease?

Question by Pamela: pulminary hypertension disease? Best answer: Answer by TweetyBirdYes? Pulmonary hypertension. What about it? Pulmonary hypertension is a type of high blood pressure that affects only the arteries in the lungs and the right side of your heart. It’s also called pulmonary arterial hypertension and PAH for short. Pulmonary hypertension begins when tiny arteries in your lungs, called pulmonary arteries, and capillaries become narrowed, blocked or destroyed. This makes it harder for blood to flow through your lungs, …

Opsumit approved by SwissMedic for pulmonary arterial hypertension

ALLSCHWIL/BASEL, SWITZERLAND – 14 February 2014 – Actelion Ltd (ATLN.VX) announced today that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.
Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality. Opsumit is effective when used as monotherapy or in combination with phosphodiesterase-5 inhibitors or inhaled / oral prostanoids. Jean-Paul Clozel, Chief Executive Officer of Actelion commented; “The SwissMedic approval, as one of the reference health authorities, is another positive step for Actelion and Opsumit in the global approval process. We are very proud that the convincing data from the SERAPHIN study and the translation into a label today, means that patients with PAH here in Switzerland can be treated with Opsumit. We will cooperate with the Swiss authorities to ensure availability for patients in due course.” The SwissMedic approval was based on data from the landmark Phase III SERAPHIN study. In the SERAPHIN study, treatment with macitentan 10 mg resulted in a 45% risk reduction (hazard ratio 0.55; 97.5% CI: 0.39 to 0.76; logrank p
The most commonly reported adverse drug reactions are nasopharyngitis (14%), headache (14%) and anaemia (13%). The majority of adverse reactions are mild to moderate in intensity.     ###   ABOUT OPSUMIT® (MACITENTAN) Opsumit (macitentan) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target of developing an ERA to address efficacy and safety [2,3]. ABOUT THE SERAPHIN STUDY SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) was the largest and longest randomized, controlled study in PAH patients to include a clearly defined morbidity/mortality primary endpoint [1]. The pivotal Phase III study was designed to evaluate the efficacy and safety of Opsumit (macitentan) – a novel dual endothelin receptor antagonist that resulted from a tailored drug discovery process – through the primary endpoint of time to first morbidity and all-cause mortality event in patients with symptomatic PAH. Global enrolment was completed in December 2009 with a total of 742 patients. Patients were randomized 1:1:1 to receive two different doses of macitentan (3 mg and 10 mg once daily) or placebo. Patients were allowed to receive PAH background therapy throughout the study, either PDE-5 inhibitors or oral/inhaled prostanoids. This event-driven study was conducted in 151 centers from almost 40 countries in North America, Latin America, Europe, Asia-Pacific and Africa and was completed in the first half of 2012, with 287 patients having an adjudicated event. ABOUT SERAPHIN STUDY DATA Patients were randomized to placebo (n=250), macitentan 3 mg (n=250), or macitentan 10 mg (n=242). The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, respectively. The hazard ratio for macitentan 3 mg versus placebo was 0.70 (97.5% CI, 0.52 to 0.96; p=0.0108) and the hazard ratio for macitentan 10 mg versus placebo was 0.55 (97.5% CI, 0.39 to 0.76; p
ABOUT THE SAFETY AND TOLERABILITY PROFILE The most commonly reported adverse drug reactions with Opsumit are nasopharyngitis (14.0%), headache (13.6%) and anaemia (13.2%).  ABOUT OPSUMIT (MACITENTAN) SUBMISSIONS TO HEALTHCARE AUTHORITIES The first approval globally of the new drug application for Opsumit (macitentan) was issued by the US Food and Drug Administration (FDA) on 18 October 2013 for the treatment of pulmonary arterial hypertension. Opsumit (macitentan) is also approved for PAH in the EU, Canada, and Australia.  Regulatory reviews in other countries are ongoing. ABOUT PULMONARY ARTERIAL HYPERTENSION [4, 5, 6] Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The symptoms of PAH are non-specific and can range from mild breathlessness and fatigue during normal daily activity to symptoms of right heart failure and severe restrictions on exercise capacity and ultimately reduced life expectancy. PAH is one group within the classification of pulmonary hypertension (PH). This group includes idiopathic PAH, heritable PAH and PAH caused by factors which include connective tissue disease, HIV infection and congenital heart disease. The last decade has seen significant advances in the understanding of the pathophysiology of PAH, which has been paralleled with developments of treatment guidelines and new therapies. Drugs targeting the three pathways that have been established in the pathogenesis of PAH are endothelin receptor antagonists (ERAs), prostacyclins and phosphodiesterase-5 inhibitors. PAH treatments have transformed the prognosis for PAH patients from symptomatic improvements in exercise tolerance 10 years ago to delayed disease progression today. Improved disease awareness and evidence-based guidelines developed from randomized controlled clinical trial data have highlighted the need for early intervention, goal-oriented treatment and combination therapy. In PAH, survival rates are unacceptably low and PAH remains incurable.   References
Pulido T et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013;369:809-18. Bolli MH et al. The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N`-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist. J Med Chem. 2012; 55:7849-61. Iglarz M. et al. Pharmacology of macitentan, an orally active tissue targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736-745. Proceedings of the 4th world symposium on pulmonary hypertension. J Am CollCardiol 2009;54(1 Suppl). Galiè N, Hoeper MM, Humbert M, et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest 2012;142:448-56.
  Actelion Ltd. Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma. Founded in late 1997, with now close to 2,400 dedicated professionals covering all key markets around the world including the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.   For further information please contact: Roland Haefeli Senior Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36www.actelion.com The above information contains certain “forward-looking statements”, relating to the company`s business, which can be identified by the use of forward-looking terminology such as “estimates”,  “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,  “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions.  Such statements include descriptions of the company`s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company`s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Press Release PDF

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: Actelion Pharmaceuticals Ltd via GlobeNewswireHUG#1761824

Health Care Industry
Health
pulmonary hypertension
SwissMedic
endothelin receptor antagonist

  • DON’T  LEAVE  EMPTY-HANDED !!!

    Download your FREE Report on High Blood Pressure

    slide14t Just a sneak peek…

    • Choosing a healthy balanced diet
    • Electro-acupuncture treatments for hypertension
    • 10 common symptoms of high blood pressure
    • High blood pressure in children
    • Long-term complications of high blood pressure
    • How do diuretics work for high blood pressure?
    • Trans-fats are another cause of high blood pressure
    Download It Completely
    FREE

    Just Insert Your Name and email







    We will also send you a Complimentary copy of our High Blood Pressure Newsletter. Our newsletter subscription has the latest information on High Blood Pressure and Hypertension treatments.

    We respect your privacy. We will NEVER sell, rent or share your email address. That’s more than a policy, it’s our personal guarantee!

  • Now you can have the Latest News on High Blood Pressure

    hiblp02-220

    Worried about High Blood Pressure and Hypertension? You can have now information about the latest treatments and medical research. All this and more in our High Blood Pressure Newsletter.slide13t

    Try it for four weeks. We will even send you FREE our bonus health e-book with your trial subscription.

    All for just ONE PENNY

    Get the latest information – don’t be left in the dark on your condition.

     CLICK HERE 

    Check our special offer: Subscribe to one newsletter, get another newsletter for FREE!